Total Payments
$702,483
2024 Payments
$142,443
Companies
33
Transactions
1,523
Medicare Patients
6,270
Medicare Billing
$339,838
Payment Breakdown by Category
Other$562,621 (80.1%)
Travel$71,963 (10.2%)
Consulting$46,750 (6.7%)
Food & Beverage$21,001 (3.0%)
Education$149.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $554,692 | 300 | 79.0% |
| Travel and Lodging | $71,963 | 367 | 10.2% |
| Consulting Fee | $46,750 | 44 | 6.7% |
| Food and Beverage | $21,001 | 804 | 3.0% |
| Honoraria | $7,885 | 5 | 1.1% |
| Education | $149.00 | 2 | 0.0% |
| Grant | $43.95 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $231,816 | 438 | $0 (2024) |
| Lilly USA, LLC | $130,388 | 222 | $0 (2024) |
| Dermavant Sciences, Inc. | $89,657 | 92 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $74,441 | 130 | $0 (2024) |
| PFIZER INC. | $72,372 | 148 | $0 (2024) |
| LEO Pharma Inc. | $55,975 | 103 | $0 (2024) |
| Incyte Corporation | $33,006 | 56 | $0 (2024) |
| DERMIRA, INC. | $10,116 | 15 | $0 (2021) |
| ABBVIE INC. | $1,201 | 102 | $0 (2024) |
| UCB, Inc. | $958.05 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142,443 | 260 | Dermavant Sciences, Inc. ($52,458) |
| 2023 | $162,092 | 279 | Lilly USA, LLC ($52,731) |
| 2022 | $76,640 | 165 | Lilly USA, LLC ($28,380) |
| 2021 | $33,257 | 116 | Lilly USA, LLC ($15,880) |
| 2020 | $30,959 | 103 | Galderma Laboratories, L.P. ($26,888) |
| 2019 | $87,013 | 178 | Galderma Laboratories, L.P. ($31,846) |
| 2018 | $57,610 | 187 | Galderma Laboratories, L.P. ($35,988) |
| 2017 | $112,470 | 235 | Galderma Laboratories, L.P. ($49,389) |
All Payment Transactions
1,523 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 12/16/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 12/16/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 12/16/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 12/16/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 12/16/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $6.48 | General |
| Category: Inflammation & Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $8.47 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $5.24 | General |
| Category: DERMATOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Immunology | ||||||
| 11/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 11/19/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 11/19/2024 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ACNE | ||||||
| 11/19/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $3.68 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,693 | 2,042 | $307,395 | $89,083 |
| 2022 | 13 | 1,594 | 1,977 | $296,047 | $85,997 |
| 2021 | 13 | 1,611 | 2,044 | $308,414 | $95,543 |
| 2020 | 13 | 1,372 | 1,590 | $249,698 | $69,214 |
Total Patients
6,270
Total Services
7,653
Medicare Billing
$339,838
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 360 | 455 | $65,520 | $25,036 | 38.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 590 | 696 | $87,000 | $22,106 | 25.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 199 | 216 | $49,680 | $13,112 | 26.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 151 | 170 | $28,050 | $6,067 | 21.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 85 | 85 | $17,425 | $5,461 | 31.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 45 | 46 | $9,936 | $3,971 | 40.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 24 | 32 | $11,584 | $3,720 | 32.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 70 | 70 | $12,460 | $2,746 | 22.0% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 23 | 24 | $6,984 | $2,424 | 34.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 34 | 48 | $7,008 | $1,631 | 23.3% |
| 17271 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 11 | 14 | $4,774 | $1,421 | 29.8% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 16 | 20 | $2,480 | $774.18 | 31.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 70 | 148 | $3,774 | $600.33 | 15.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 18 | $720.00 | $13.75 | 1.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 424 | 512 | $73,728 | $25,787 | 35.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 443 | 518 | $64,750 | $17,253 | 26.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 204 | 231 | $53,130 | $14,539 | 27.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 96 | 96 | $19,680 | $5,717 | 29.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 55 | 56 | $12,096 | $4,259 | 35.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 102 | 110 | $18,150 | $4,045 | 22.3% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 33 | 33 | $11,946 | $3,914 | 32.8% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2022 | 28 | 33 | $9,603 | $2,994 | 31.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 73 | 73 | $12,994 | $2,916 | 22.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 35 | 39 | $5,694 | $1,284 | 22.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 17 | 20 | $3,980 | $1,192 | 29.9% |
About Dr. Brian Williams, MD
Dr. Brian Williams, MD is a Dermatology healthcare provider based in Midvale, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235162199.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Williams, MD has received a total of $702,483 in payments from pharmaceutical and medical device companies, with $142,443 received in 2024. These payments were reported across 1,523 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($554,692).
As a Medicare-enrolled provider, Williams has provided services to 6,270 Medicare beneficiaries, totaling 7,653 services with total Medicare billing of $339,838. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Midvale, UT
- Active Since 07/07/2006
- Last Updated 12/09/2009
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1235162199
Products in Payments
- EPIDUO FORTE (Drug) $97,192
- VTAMA (Drug) $89,657
- AKLIEF (Drug) $81,088
- COSENTYX (Biological) $70,137
- OLUMIANT (Drug) $66,707
- EUCRISA (Drug) $51,261
- ADBRY (Biological) $43,675
- TALTZ (Drug) $39,367
- OPZELURA (Drug) $28,002
- ORACEA (Drug) $22,765
- CIBINQO (Drug) $19,988
- Olumiant (Drug) $10,120
- QBREXZA (Drug) $10,116
- SOOLANTRA (Drug) $8,644
- PICATO (Drug) $7,381
- ENSTILAR (Drug) $4,899
- MIRVASO (Drug) $3,996
- TWYNEO (Drug) $2,400
- COSENTYX (Drug) $1,963
- Cimzia (Drug) $763.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.